Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) FCF Margin (2017 - 2025)

Puma Biotechnology's FCF Margin history spans 9 years, with the latest figure at 19.22% for Q4 2025.

  • For Q4 2025, FCF Margin fell 723.0% year-over-year to 19.22%; the TTM value through Dec 2025 reached 18.3%, up 141.0%, while the annual FY2025 figure was 18.3%, 141.0% up from the prior year.
  • FCF Margin reached 19.22% in Q4 2025 per PBYI's latest filing, up from 17.77% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 30.22% in Q3 2022 to a low of 58.8% in Q1 2022.
  • Average FCF Margin over 5 years is 8.48%, with a median of 14.08% recorded in 2023.
  • Peak YoY movement for FCF Margin: plummeted -7476bps in 2022, then soared 6381bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 9.82% in 2021, then surged by 189bps to 8.77% in 2022, then skyrocketed by 65bps to 14.45% in 2023, then skyrocketed by 83bps to 26.45% in 2024, then fell by -27bps to 19.22% in 2025.
  • Per Business Quant, the three most recent readings for PBYI's FCF Margin are 19.22% (Q4 2025), 17.77% (Q3 2025), and 26.84% (Q2 2025).